INTRODUCTION
Rheumatoid arthritis is a systemic inflammatory disorder of chronic nature, associated with destructive synovitis, progressive cartilage and bone damage. The wide prevalence of RA, about 0.5-1% of the population worldwide, stratifies it as one of the most common autoimmune diseases. Though its exact etiology is still unknown,knowledge related to its pathogenesis is expanding and currently is thought to be driven by complex interactions of cells, like T cells, macrophages and fibroblasts (Kugyelka et al., 2016) . Previously, CD4+ lymphocytes were thought to comprise two discrete effector cells, the Th1 and Th2 subsets which are responsible for secretion of either interferon (IFN)-γ or IL4, respectively. In 2005, a third T helper cell subset,producing IL-17, was reported and called Th17 cells (Harrington et al., 2005 and Park et al., 2005) .Before Th17subset was discovered, IL-17 was suggested to originate from Th1 cells, however, IL-12 was found to inducetransformation ofhuman Th17 cells into Th1 cells (Boniface et al., 2010) . Former studies detected Th17 cells close to osteoclasts in joints of RA patients. They also suggested thatIL17promotes osteoclast differentiation, hence aggravates joint destruction and bone resorption during RA. In addition, local and systemic production of IL17 was detected during initiation of RA in animal models. 
MATERIALS & METHODS
The current study included 170 RA patients who were diagnosed according to 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria (Aletaha et al., 2010) . They were selected during regular follow-up at the outpatients' clinic and the inpatients' unit of the Rheumatology and Rehabilitation Department, Benha University Hospitals. Additional 133, age and sex matched, apparently healthy volunteers were recruited as a control group.We excluded patients who were less than 18 years old and thosepresented with overlap or association with any other rheumatic or autoimmune diseasese.gosteoarthritis, psoriatic and lupus arthritis. Control subjects with seropositive RF, CRP, ESR oranti-cyclic citrullinated peptide antibody(Anti-CCP) results were also excluded.The study scheme was approved by the ethical committee of Faculty of Medicine, Benha University andinformed consents were obtained from all participantsbefore enrollment. Upon enrollment, all patients were subjected to full history taking, complete physical examination, visual analogue scale (VAS) and disease activity assessmentusing the Disease Activity Score in 28 joints (DAS28) (Aletaha et al., 2005 Comparisons between the different studied groups were carried out using the Chi-square test (χ 2 ), Fisher's Exact Test (FET) and the test of proportion (Z) to compare proportions as appropriate. The Student t-test (t) and Mann-Whiteny test (z) were used to detect differences between two normally and non-normally distributed variables respectively, while the ANOVA (F) and Kruskal Wallis test (χ 2 ) were used to compare more than two quantitative data. Genotype frequencies in RA cases and controls were tested for Hardy-Weinberg equilibrium, and significanceof any deviation between the observed and expected frequencies was tested using Chi-square test.
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A p-value <0.05 was considered statistically significant. The statistical analysis was conducted using STATA version 11.2 (STATA corporation, College Station, Texas).
RESULTS
The current study included 170 RA patients (147 females, 86.47% and 23 males, 13.53%). Their ages ranged between 30 and 58 years with a mean of 41.49±5.57 years. Other clinical, laboratory and radiologic characteristics of the study groups are shown in table (1) genotype frequencydistribution between the controls and RA patients were insignificant (p>0.05). Regarding serum level of IL17, sera of RA patients had significantly higher levels as compared to serum samples of the controls (p< 0.05). Based on genotype classification of both studied groups, IL17 was significantly increased only in AG and GG patients compared to healthy subjects with corresponding genotypes. Importantly, within RA patients, those with GG genotype had significantly elevated serum IL 17 levels as compared to AA patients (p< 0.05). Figure (1 Within RA patients' group, comparison of various genotypesas regard mean values of DAS28 scale and ESR revealed that they were significant higherin AG patients when compared to those with AA genotype, and in GG patientscompared to AA or AG subgroups, as well (all p<0.05).In addition, the current results showed significant differences in frequency distribution of DAS28 grades with GG patients having the highest frequency of the high DAS28 grade (p<0.05). Moreover, patients who had GG genotype showed significantly higher frequencies of positive RF and CRP results, as compared to other genotypes.Higher grades of Larsen scale presented with significant association to GG genotype as well (p<0.05). In addition, the present study revealed that in patients with AG, GG genotypes, serum IL17 levels were significantly positively correlated to DAS28. However, IL17 serum levels were positively correlated to Larsen scale with significant difference only in patients with GG genotype. 
DISCUSSION
Previous studies suggested a key role for IL17 in the pathogenesis of RA and pointed to the association between IL4R SNP rs1805010, and RA joint destruction (Krabben et al., 2013) . This study was conducted on Egyptian RA patients to assess the differences in serum IL17 levelsbased on genotypes of IL4R SNP rs1805010,and to elucidate their possible association with RA clinical manifestations and treatment effect. To our knowledge, the current work is the first study in Egyptian RA patients to and focus on the relationship between IL4R genotypes and serum IL17, providing more insight on mechanism of action of IL4R with different genotypes. The role of IL4R genotypes in RA susceptibility in Egyptian patients was previously reported with contradictory results (Hussein et al., 2012 and  Mohamed etal., 2015) .The present data showed non-significant differencesin genotypes' distribution between RA patients and controls. This result supportsthe previous reports thatIL4RSNP (rs1805010) might not be relevant as a risk factor for RA disease (Burgos et al., 2010 and Hussein et al., 2012) . However, this observation was in contrast to that of Mohamed etal., 2015.
The different samople sizes and use of different technicques for detection of IL4R genotypes may explain such controversy. Studying clinical activity parameters in different genotypes, results of the current study demonstrated a significant association between rs1805010 G allele from one side and the higher DAS28, ESR values on the other side. Moreover, patients who had GG genotype presented with significantly higher frequencies of seropositive RF, CRP and higher grades of Larsen scale. In this regard, our results were similar to what was previously reported. After follow up for one year, Leipe and colleagues, 2014 demonstrated that carriers of G variant had significantly higher DAS28 scores than healthy controls.As well, an Egyptian study found that RF seropositivity and bone erosions associated significantly withG allele of IL4R (Hussein et al., 2012) . Other reports suggested that carrying G allele was predictive of more severe erosive disease (Leipe et al., 2014 and Prots et al., 2006). Additional evidence was provided by another research group as they stated that moderate DAS scores was found in AG patients while GG patients showed higher scores. They added that though their observation was statistically insignificant, yet it reflects higher disease activity in GG genotype of rs1805010 (Wallis et al., 2011) . However, one study in African American patients with RA, failed to detect any significant association between genotypes of rs1805010 and RF status, Anti-CCP or radiographic erosions. Such discrepancy may be attributed to different studied races, patients' characteristics and effect of treatment.
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IL4 has been shown to be highly protective cytokine in RA due to its ability to suppress inflammation and joint destruction through many mechanisms. It inhibits production of vascular endothelial growth factor thus possesses antiangiogenic effect, inhibits osteoclastic activity and downregulatestissue metalloproteinase-1 expression and so decreases cartilage destruction (Wallis  et al., 2011) .Interestingly, binding of IL4 to its receptor activates signal transducer and activator of transcription-6 (STAT6)which upregulates a wide range of genes necessary for Th2differentiation of CD4 T cells.In turn, enhanced differentiation to Th2 cells allows further increase of its product; IL4. (Prots et al., 2006) .. Though IL4R rs1805010 is located near IL4-binding site, prior reports suggested that its effect is mediated through modulating the action of STAT6, rather than changing the affinity for IL4. It has been shown that IL4R-A allele confers protectionin RA patients, through prolonged STAT6 activation, thus increased IL4 production, while the G variant is associated with higher disease activity and rapidly developing erosions due to diminished STAT6 activation and decreased IL4 production (Hussein et al., 2012; Leipe et al., 2014 and Prots et al., 2006) In addition, assessment of serum IL17 revealed significantly higher levels in RApatients compared withcontrol subjects,which is consistent with the results of previous studies in earlyas well as in established RA. genotypes, demonstrated that the presence of G allele conferred significant increase of IL17 in patients as compared to corresponding controls. Furthermore,patients with GG genotype had the highest serum IL17 levels, followed by AG then AA genotypes. However, such differences were statistically significant onlyin between GG and AA patients.On the other hand, serum IL17 showed non-significant differences between the three genotypes in the control group. In line with these data,Leipe and colleagues, 2014demonstrated that presence of even one G allele was associated with significantly higher frequency of Th 17 and IL17 production in RA patients. Furthermore, the present studydetected significant positive correlations between serum IL17 and DAS28 score in patients carrying AG and GG genotypes. However, only GG carriers showeda positive correlation with statistical significance between serum IL17 and Larsen scale. Our results highlight the poor effect of IL4RG allele on RA progression, a process in which IL-17 seems to be a crucial player.Interestingly, IL4 has been shown todecrease autoimmune inflammation, bone and joint destruction not only through above mentioned mechanisms but also by suppression of Th17/IL17 axis and effects Guenova et al., 2015; Leipe et al., 2014 and Wallis et al., 2011) . The current findings might be explained by the reduced ability of IL4 to suppress Th17 cells in carriers of G allele. Amino acid substitution due to rs1805010 GG genotype, reduces STAT6 activation, hence weakens the downstream signals through IL4R. Thus, production of IL4 is significantly diminished and TH17/IL17 suppression is diminished as well, in such patients Guenova et al., 2015; Leipe et al., 2014 and Wallis et al., 2011) . Finally, there were non-significant differences in serum levels of IL17 between patients on different treatment regimens in all three genotypes. In this regard, the present study was limited because all included patients were using conventional DMARDs due to very high cost of other biologic drugs. CONCLUSION : In conclusion,IL17 may play a role in progression of RA disease.However, clinical effects of IL17 become more evident due to loss of suppression by IL4 in paƟents with hypofuncƟonalIL4R of GG genotype. Determining IL4Rrs1805010 geneƟc variants, may allow early identification of those at risk of high disease activityfor special therapeutic approachto reduce morbidity as possible. To establish the benefit of such patients from treatment depending on anti-IL17 rather than IL4 mechanisms, further longitudinal cohort studies are needed,with a larger sample size focusing on new biologic treatment strategies and their outcome.
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